🔗 Share this article

While the United States continues making unprecedented changes to its immunization schedules, one figure has surfaced in a surprising turn: Tracy Beth Høeg, a US-based sports medicine doctor and epidemiologist who rose to prominence by questioning Covid shots throughout the global health crisis and has concentrated on possible deaths after COVID-19 vaccination in her recent position at the Food and Drug Administration.

Scheduled Changes to Pediatric Immunization Schedule

Public health authorities had intended to unveil sweeping changes to the pediatric vaccine schedule recently, bringing the US with Denmark’s vaccine program, it is understood – a significant shift that would place the US out of step with many the international standard with no evidence for improved outcomes. The planned update has been postponed until the next year.

Instead of Vinay Prasad, Høeg is set to speak at the gathering. She was recently named interim head of the FDA’s CDER, the fifth appointee to lead the division this calendar year.

A Shift at the FDA

The acting appointment might represent a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Dr. Prasad solidify control at the agency – and it suggests a increased emphasis upon rolling back long-standing vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing some pediatric shot schedules in the US so as to align more in line with Denmark's approach, a country with nationalized medicine and a number of inhabitants approximately the population of the state of Wisconsin.

In her initial public appearances, she has persisted in emphasizing on immunizations – traditionally the purview of Prasad, chief of the FDA’s vaccine center – instead of drug regulation.

Doubts Over Expertise

Høeg has little discernible track record in pharmaceutical research, regulation or management, which has been standard for previous directors of the CBER. She has worked at the FDA as a key advisor to the agency head and the vaccine center since March.

“She doesn’t seem to have the necessary background” for running the CDER, said Jonathan Howard. “She lacks experience running a scientific study. She is not versed in running a major agency. She is not an expert in industry regulation.”

Past directors of the center would “understand laws and regulations and the science of drug development”, noted a former acting FDA commissioner. “Objectively, she doesn’t have the sort of resume that previous people who headed the center have had.”

CDER has an immense range of responsibilities at the FDA, the former commissioner pointed out.

“Everybody just zeroes in on the new drug program, but the generic drug division approves numerous generic medications. There is also a biosimilars division, OTC medication office and so forth, and each of these have to be managed,” she noted. “The responsibility you neglect, that is precisely what that I always told people is going to cause problems.”

Furthermore, a significant management aspect to the job, which oversees more than 5,000 staff members. “It’s a massive administrative position, if you execute it properly,” Woodcock said.

Agency Reaction and Contentious Initiatives

Regarding concerns about Høeg’s fitness for the role and whether this appointment represents more teamwork among FDA leaders on vaccines, a spokesperson said that the “inquiries stem from inaccurate assumptions”.

“Her experience aligns with the responsibilities of her position,” the spokesperson stated, citing the months Dr. Høeg spent advising the FDA commissioner on “pharmaceutical safety and approval science, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Dr. Høeg inherits the agency head's new priority voucher program, a disputed one-day therapy clearance system that apparently troubled her predecessors. “How are these medications being selected for this fast-track system? Who takes the calls?” Howard questioned. “There is a lot of secrecy going on at the regulatory body right now.”

In general, he remarked, “the FDA seems to be moving towards more relaxed rules of all drugs, except for vaccines.”

Public Track Record on Vaccines

Concerning immunizations, Høeg has a more established, if concerning, track record, critics have noted. She published a study using non-validated volunteer-provided data to estimate the incidence of myocarditis after Covid immunization. She counseled the state of Florida top health official Joseph Ladapo, who allegedly have changed statistics to indicate COVID-19 vaccinations are more dangerous than they are.

Among her “wish list” for the new government included revising guidelines for recently developed shots and ending “unnecessary” immunizations, she stated post-election on a audio program. At the agency, Høeg has according to sources suggested barring young men from getting Covid vaccinations.

“She is an all-around true believer who starts off with her conclusions and reverse-engineers to fit the science in a extremely disingenuous, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with fellow contrarians, {like|